The University of Oxford launched the first human trial of a vaccine against Bundibugyo ebolavirus on July 13, 2026, as the outbreak in the Democratic Republic of Congo spread into two more northeastern provinces and the machinery of global health raced to catch up. The early-stage trial, called BD-Ebov, will test the safety and immune response of the ChAdOx1 BDBV vaccine in 50 healthy adults aged 18 to 55 in Oxford. Recruitment has begun. Vaccinations are expected to start in the coming weeks, pending regulatory approval.
Who Gets the Risk, Who Gets the Credit
The people facing Ebola in Congo are not the ones getting enrolled in Oxford’s first human trial. That trial is being run on 50 healthy adults in Oxford, while the outbreak itself has already reached 1,926 confirmed cases and 702 deaths, according to official data late on Sunday. The gap is hard to miss. One side gets monitored in a university setting. The other side lives with a disease that spreads through direct contact with bodily fluids from infected people or animals and can cause high fever, vomiting and internal and external bleeding.
The vaccine was developed by scientists at Oxford's Vaccine Group and Pandemic Sciences Institute using the same viral vector platform as the Oxford/AstraZeneca COVID-19 shot. Serum Institute of India, which is partnering on the programme, said it manufactured and stockpiled about 620,000 doses of the vaccine candidate within two weeks and supplied 4,000 investigational doses for the early-stage study. The speed is striking. So is the structure. A handful of institutions decide what gets built, where it gets tested, and which populations wait for the results.
In May, the World Health Organization recommended prioritising ChAdOx1 BDBV vaccine, alongside a single-dose candidate known as rVSV Bundibugyo, being developed by the International AIDS Vaccine Initiative, for clinical evaluation as part of the response to the ongoing outbreak. The language is clinical. The hierarchy is not. Global agencies recommend, universities trial, manufacturers stockpile, and the people in the outbreak zone live inside the consequences.
The Outbreak Keeps Moving
The Ebola outbreak in the Democratic Republic of Congo has now spread to Haut-Uele and Tshopo, the country's public health institute said in its latest report. Four cases were recorded in Tshopo, including two deaths, with one death confirmed in Haut-Uele, as of Saturday. The latest outbreak, Congo's 17th, was declared on May 15 and has been largely concentrated in Ituri province, with cases also reported in North Kivu and South Kivu provinces.
Reuters reported in late June that Congolese health authorities had started tracing people potentially exposed to Ebola in Tshopo and Haut-Uele, but until now the two provinces had not been included in the government's daily reports. That detail matters. The state’s reporting apparatus lags behind the spread of the disease, while the virus doesn’t wait for paperwork.
"Although current investigations suggest that all cases detected in these two provinces are primarily imported from Niania in Ituri, it is necessary and appropriate ... to consider these two provinces as an epidemic zone," the National Institute of Public Health said in its report dated July 11. Tshopo's provincial capital is Kisangani, one of Congo's largest cities. Haut-Uele shares borders with South Sudan and the Central African Republic. The outbreak is moving across borders, provinces, and official categories faster than the institutions can contain it.
What the Institutions Promise
The Coalition for Epidemic Preparedness Innovations said it would initially invest up to $8.6 million for the development of the shot. Preparations are also under way for additional clinical studies in Uganda, subject to regulatory approval, through partnerships including the Medical Research Council/Uganda Virus Research Institute and the London School of Hygiene and Tropical Medicine Uganda Research Unit. If the early-stage trial is successful, CEPI said it would work with Oxford and Serum Institute to support late-stage studies needed to seek emergency-use authorisation or full regulatory approval.
The partners said they aim to ensure rapid and affordable vaccine supplies for affected countries. That’s the promise. The actual arrangement still runs through approvals, trials, institutions, and funding decisions made far from the people most exposed to the outbreak.
A senior World Health Organization official told Reuters last week that the true scale of the outbreak could be two to four times larger than official data indicate because four out of five new Ebola cases have no known link to existing patients. That estimate hangs over the whole response. The numbers on paper may be smaller than the crisis on the ground, and the people living through it are left to absorb the difference.